DOCSLIB.ORG

PND Releases a 200+ Page Catalog for Vitanova Signature

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PND Releases a 200+ Page Catalog for Vitanova Signature TM VITANOV A Signature America's Best Choice TM ® ® CREATING A HEALTHY WORLDTM CREATING A HEALTHY WORLDTM Pharmapex's Nutrition Department PHARMAPex’swww.Pharmapex.net NutritioN DEPARTMENT www. Pharmapex.net @2016, Pharmapex Group, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: +1.619.881.0035 [email protected] MEGAFOOD CREATING A HEALTHY WORLD™ www.Pharmapex.net ® CREATING A HEALTHY WORLDTM Vitanova Signature America's Best Choice™ ™ A Product of Pharmapex's Nutrition Department Toll-Free: 1.844.PHARMAPEX Fax: +1.619.881.0035 [email protected] VITANOVA SIGNATURE™ CREATING A HEALTHY WORLD™ www.Pharmapex.net PHARMAPEX GROUP & NUTRITION INDUSTRY Pharmapex Group is a leader in manufacturing, supply, and distribution of nutritional supplements and medicated food products in the nutrition industry. Nutritional Supplements With nearly 200 SKU's and 150 products to choose from, we manufacture our high quality nutritional supplement products in a new state-of-the art 132,000 square feet, environmentally-friendly production facility. With new investments, this facility is able to blend up to 200,000 kilos, and produce up to 120 million tablets, 140 million capsules and 1 million bottles per month with its current equipment. These quality products range from Acai and Resveratrol to a number of proprietary products such as Heart-Cholesterol Support and Brain Formula to aide in boosting energy and focus. Major Product Classes: • Amino Acids • Nutrient Enhancer • Antioxidants • Organics • B-Complex • Personal Care • Cleansing & Fiber • Protein • Diet & Weight Control • Special Needs • Energy • Sports Nutrition • Enzymes • Stress Formulas • Essential Fatty Acids • Vitamin A & D • Herbs • Vitamin C • Individual B Vitamins • Vitamin E • Lipotropics • Vitamin K • Minerals • Whole Foods • Multi-Vitamins Major Structure Functions: • Amino Acids • Amino Acids • Antioxidants • Antioxidants • B-Complex • B-Complex • Cleansing & Fiber • Cleansing & Fiber • Diet & Weight Control • Diet & Weight Control • Energy • Energy • Enzymes • Enzymes • Essential Fatty Acids • Essential Fatty Acids • Herbs • Herbs • Individual B Vitamins • Individual B Vitamins • Lipotropics • Lipotropics • Minerals • Minerals • Multi-Vitamins • Multi-Vitamins ‹ 1 › Toll-Free: 1.844.PHARMAPEX Fax: +1.619.881.0035 [email protected] VITANOVA SIGNATURE™ CREATING A HEALTHY WORLD™ www.Pharmapex.net We manufacture our products in four major forms, namely tablets, capsules, softgels, and powders. Also, the superior packaging of our products that comes with photo quality labels is unrivalled in the industry. Specically, we offer our products in the following packaging formats: PND Packaging of Nutritional Supplements: A. PCR Bottles – Responsible Packaging Pharmapex's Nutrition Department (PND) is committed to renewable packaging sources. By using a large volume of Post Consumer Recycled (PCR) PET Amber bottles in the nutritional industry, we have set the bar by which other manufacturers will be measured. B. Blister Packs – High End Packaging PND now offers its products in blister packaging for those who are looking for a high end pharmaceutical feel for our products. Blisters offer great product stability and visibility of the actual dosage form. Blisters are also perfect for increasing the consistency of use by end consumers because they offer an easy way to take our products on the go. Our group has the capacity to produce up to 700,000 blister packs of its products per month. C. Pouches – Convenient Consistency Convenience is important in today’s fast paced life style. Single serve pouches offer the exibility that canisters just can’t offer. They are also great marketing tools. Customized pouches with our product branding on them will be in front of your customer and those around them at the gym, ofce or on the road. PND offers its products based on a full range of sizes of single serve pouches. Our group has the capacity to produce 2.5 million pouches of our products per month. D. Packets – Endless Possibilities PND now offers its products in a variety of nished tablets, capsules and softgels in a single packet. With most vitamin consumers taking a variety of products each day, packets have become a great way to combine the most popular products into one convenient package. They are easy to throw in one’s purse or briefcase and take on the road so that a consistent regimen can be maintained by the end user. Packets have opened the door to an entirely separate segment in the nutrition industry. Our group has the capacity to produce up to 2.5 million packets of its products per month. E. Stick Packs – Nutrition with a Twist For many years, people throughout certain parts of the world have enjoyed the ease of use of powders packaged in stick packs, as the thinner form allows for easier mixing of products in water bottles. This packaging form is becoming more and more popular every day. In order to better serve its customers, PND now offers stick packing as yet another packaging possibility for its products. Its sleek design and ease of use are just a few of the marketing advantages of this great new packaging. Our group has the capacity to produce up to 2 million stick packs of its products per month. ‹ 2 › Toll-Free: 1.844.PHARMAPEX Fax: +1.619.881.0035 [email protected] VITANOVA SIGNATURE™ CREATING A HEALTHY WORLD™ www.Pharmapex.net VITANOVA™ SIGNATURE LINE OF PRODUCTS BY CATEGORY: NAME COUNT FORM PRODUCT # CATEGORY PAGE # Amino Complex 50/CT Capsules VNV000 Amino Acids 9-11 Amino Complex 100/CT Capsules VNV001 Amino Acids 9-11 L-Arginine 500 mg 50/CT V-Caps VNV002 Amino Acids 12 L-Arginine 500 mg 100/CT V-Caps VNV003 Amino Acids 12 L-Carnitine 250 mg 30/CT V-Caps VNV004 Amino Acids 13 L-Carnitine 250 mg 60/CT V-Caps VNV005 Amino Acids 13 L-Cysteine 500 mg 100/CT Capsules VNV006 Amino Acids 14 L-Glutamine 500 mg 100/CT V-Caps VNV009 Amino Acids 15 L-Lysine 500 mg 100/CT V-Caps VNV011 Amino Acids 16 L-Tyrosine 500 mg 50/CT Capsules VNV012 Amino Acids 204 L-Tyrosine 500 mg 100/CT Capsules VNV013 Amino Acids 204 Taurine 500mg 60/CT V-Caps VNV014 Amino Acids 17 5 HTP 50 mg 90/CT V-Caps VNV015 Amino Acids 18 Antioxidant Complex 120/CT Tablets VNV031 Antioxidants 19-21 Alpha Lipoic Acid 60/CT Tablets VNV032 Antioxidants 205 Co-Q10 100 mg 60/CT V-Caps VNV034 Antioxidants 22 Co-Q10 30 mg 30/CT V-Caps VNV035 Antioxidants 23 Co-Q10 30 mg 120/CT V-Caps VNV037 Antioxidants 23 Co-Q10 60 mg 60/CT V-Caps VNV039 Antioxidants 24 Co-Q10 60 mg 120/CT V-Caps VNV040 Antioxidants 24 Co-Q10 60 mg 30/CT V-Caps VNV041 Antioxidants 24 Grapeseed Extract 100 mg 120/CT V-Caps VNV043 Antioxidants 25 Co-Q10 100 mg 60/CT Softgels VNV046 Antioxidants 22 Lycopene 60/CT Softgels VNV047 Antioxidants 26 Resveratrol 60/CT Tablets VNV048 Antioxidants 27 Ultimate B Complex 90/CT Tablets VNV061 B Vitamins 28-29 Ultimate B Complex 60/CT Tablets VNV062 B Vitamins 28-29 B Complex 100/CT Tablets VNV063 B Vitamins 30-32 Biotin 500 mcg 60/CT V-Caps VNV064 B Vitamins 33 Folic Acid 800 mcg 100/CT Tablets VNV065 B Vitamins 34 Folic Acid 800 mcg 250/CT Tablets VNV066 B Vitamins 34 Niacin (no flush) 300 mg 120/CT V-Caps VNV068 B Vitamins 35 Ultimate B-1 100 mg 100/CT V-Caps VNV070 B Vitamins 36 Ultimate B-12 500 mcg 50/CT Tablets VNV071 B Vitamins 37 Ultimate B-12 500 mcg 100/CT Tablets VNV072 B Vitamins 37 Vitamin B-6 25 mg 90/CT Tablets VNV075 B Vitamins 38 Borage Oil 1,000 mg 90/CT Softgels VNV091 Essential Fatty Acids 39 DHA 100 mg 60/CT Softgels VNV092 Essential Fatty Acids 40 Evening Primrose Oil 500 mg 240/CT Softgels VNV094 Essential Fatty Acids 41 Evening Primrose Oil 500 mg 60/CT Softgels VNV095 Essential Fatty Acids 41 ‹ 3 › Toll-Free: 1.844.PHARMAPEX Fax: +1.619.881.0035 [email protected] VITANOVA SIGNATURE™ CREATING A HEALTHY WORLD™ www.Pharmapex.net NAME COUNT FORM PRODUCT # CATEGORY PAGE # Evening Primrose Oil 500 mg 120/CT Softgels VNV096 Essential Fatty Acids 41 Fish Oil 50/CT Softgels VNV097 Essential Fatty Acids 42-43 Fish Oil 100/CT Softgels VNV098 Essential Fatty Acids 42-43 Flax Seed Oil 1,000 mg 60/CT Softgels VNV099 Essential Fatty Acids 44 Flax Seed Oil 1,000 mg 120/CT Softgels VNV100 Essential Fatty Acids 44 Mega Potency Fish Oil 60/CT Softgels VNV102 Essential Fatty Acids 45-46 Children’s DHA 120/CT Softgels VNV104 Essential Fatty Acids 47 Cod Liver Oil 120/CT Softgels VNV105 Essential Fatty Acids 48 Evening Primrose Oil 1300 mg 60/CT Softgels VNV106 Essential Fatty Acids 49 DHA 200 mg 60/CT Softgels VNV107 Essential Fatty Acids 50 Astragalus 500 mg 60/CT V-Caps VNV121 Herbs 51 Bilberry 90 mg 120/CT V-Caps VNV124 Herbs 52 Black Cohosh 100 mg 120/CT V-Caps VNV126 Herbs 53 Echinacea 250 mg 60/CT V-Caps VNV127 Herbs 54 Echinacea and Goldenseal 60/CT V-Caps VNV128 Herbs 55-56 Echinacea Blend 100/CT V-Caps VNV130 Herbs 57 Odorless Garlic 500 MG 120/CT Tablets VNV132 Herbs 58 Ginger 250 mg 120/CT V-Caps VNV135 Herbs 59 Ginkgo 60 mg 240/CT V-Caps VNV136 Herbs 60 Ginkgo 60 mg 120/CT V-Caps VNV137 Herbs 60 Ginkgo 60 mg 60/CT V-Caps VNV138 Herbs 60 Hawthorn 300 mg 120/CT V-Caps VNV141 Herbs 61 Milk Thistle 100 mg 60/CT V-Caps VNV144 Herbs 62 Milk Thistle 100 mg 120/CT V-Caps VNV145 Herbs 62 Nettles 400 mg 60/CT V-Caps VNV146 Herbs 63 Panax Ginseng 200 mg 120/CT V-Caps VNV147 Herbs 64 Saw Palmetto 160 mg 60/CT Softgels VNV149 Herbs 65 Saw Palmetto 160 mg 240/CT Softgels VNV151 Herbs 65 Soy Isoflavones 60/CT V-Caps VNV154 Herbs 66 St.
Load more

Recommended publications
  • Cutaneous Manifestations of Systemic Diseases 428 C2 Notes Dr
    Cutaneous Manifestations of systemic diseases 428 C2 Notes Dr. Eman Almukhadeb Cutaneous Manifestations of systemic diseases Dr. Eman Almukhadeb CUTANEOUS MANIFESTATIONS OF DIABETES MELLITUS: Specific manifestations: 1 Cutaneous Manifestations of systemic diseases 428 C2 Notes Dr. Eman Almukhadeb 1. Diabetes dermopathy or “SHIN SPOTS”: Most common cutaneous manifestation of diabetes; M > F, males over age 50 years with long standing diabetes. They are: bilateral, symmetrical, atrophic red-brownish macules and patches, over the shins mainly but can occur at any sites, asymptomatic. There is no effective treatment. 2. Necrobiosis Lipoidica Diabeticorum (NLD): Patients classically present with single or multiple red-brown papules, which progress to sharply demarcated yellow-brown atrophic, telangiectatic erythematic plaques with a violaceous, irregular border. Usually it’s unilateral. Common sites include shins followed by ankles, calves, thighs and feet. Very atrophic plaque so any trauma will lead to ulceration, it occurs in about 35% of cases. Cutaneous anesthesia, hypohidrosis and partial alopecia can be found Pathology: Palisading granulomas containing degenerating collagen. The nonenzymatic glycosylation of dermal collagen and elastin will lead to degeneration of the collagen and atrophy (necrobiosis). 2 Cutaneous Manifestations of systemic diseases 428 C2 Notes Dr. Eman Almukhadeb Approximately 60% of NLD patients have diabetes and 20% have glucose intolerance. Conversely, up to 3% of diabetics have NLD, so if a patient has NLD its common that he is diabetic, but not every diabetic patient have NLD. (Important) Women are more affected than men. Treatment: Ulcer prevention (by avoiding trauma). No impact of tight glucose control on likelihood of developing NLD. There are multiple treatment options available and all of them reported to be effective: o Intralesional steroids o Systemic aspirin: 300mg/day and dipyridamole: 75 mg/day.
    [Show full text]
  • Overall Skin Tone and Skin-Lightening-Improving Effects with Oral Supplementation of Lutein and Zeaxanthin Isomers: a Double-Blind, Placebo‑Controlled Clinical Trial
    Journal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: ORIGINAL RESEARCH Year: 2016 Volume: 9 Clinical, Cosmetic and Investigational Dermatology Dovepress Running head verso: Juturu et al Running head recto: L/Zi supplementation improves overall skin tone and skin lightening open access to scientific and medical research DOI: http://dx.doi.org/10.2147/CCID.S115519 Open Access Full Text Article ORIGINAL RESEARCH Overall skin tone and skin-lightening-improving effects with oral supplementation of lutein and zeaxanthin isomers: a double-blind, placebo-controlled clinical trial Vijaya Juturu1 Purpose: Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and James P Bowman2 protect skin from environmental factors including high-energy sources. These carotenoids may be Jayant Deshpande1 able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants. Subjects and methods: This is a randomized, double-blind, placebo-controlled clinical 1Department of Scientific and Clinical Affairs, OmniActive Health trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were Technologies Inc., Morristown, NJ, recruited and 46 subjects completed the study) (males and females, age: 18–45 years) with 2 James P Bowman & Associates LLC, mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified Loveland, OH, USA as Fitzpatrick skin type II–IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: RR-zeaxanthin and RS (meso)-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter®.
    [Show full text]
  • Éditeur Officiel Du Québec
    1 0 © Québec Official Publisher Updated to October 31, 2020 This document has official status. chapter P-29, r. 1 Regulation respecting food A G Food Products Act R I(chapter P-29, s. 40). CP U0- 4A2 L The fees prescribed in the Regulation have been indexed as of 1 April 2019 pursuant to the notice p9 T published in Part 1 (French) of the Gazette officielle du Québec of 16 March 2019, page 255. (ss. r U 1.3.6.1, 1.3.6.2, 1.3.6.3, 1.3.6.4, 1.3.6.5, 1.3.6.6, 1.3.6.7, 1.3.6.7.3, 1.3.6.7.4, 1.3.6.7.5, 1.3.6.7.6, i R 1.3.6.7.7, 1.3.6.7.8, 1.3.6.10, 1.3.6.12) Al L0 TABLEP1 OF CONTENTS R O2 CHAPTER 1 D0 GENERAL PROVISIONS U1 DIVISION 1.1 C6 APPLICATION — DEFINITIONS.................................................................... 1.1.1 T S DIVISION 1.2 — REGISTRATION................................................................................................ 1.2.1 F O DIVISION 1.3 O PERMIT D § 1.3.1. — General provisions.............................................................................. 1.3.1.1 § 1.3.2. — Categories of slaughterhouse permit.................................................. 1.3.2.1 § 1.3.3. — Categories of permits for plants for the preparation, conditioning or processing, for wholesale purposes, of meat or meat products intended for human consumption........................................................................................... 1.3.3.1 § 1.3.4. — Categories of dismembering plant permit........................................... 1.3.4.1 § 1.3.5. — Categories of permits to salvage inedible meat.................................. 1.3.5.1 § 1.3.5.A.
    [Show full text]
  • Safety Assessment of Punica Granatum (Pomegranate)-Derived Ingredients As Used in Cosmetics
    Safety Assessment of Punica granatum (Pomegranate)-Derived Ingredients as Used in Cosmetics Status: Draft Final Report for Panel Review Release Date: May 15, 2020 Panel Meeting Date: June 8-9, 2020 The Expert Panel for Cosmetic Ingredient Safety members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Lisa A. Peterson, Ph.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The Cosmetic Ingredient Review (CIR) Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Christina L. Burnett, Senior Scientific Analyst/Writer, CIR. © Cosmetic Ingredient Review 1620 L St NW, Suite 1200 ◊ Washington, DC 20036-4702 ◊ ph 202.331.0651 ◊fax 202.331.0088 ◊ [email protected] Distributed for Comment Only -- Do Not Cite or Quote Commitment & Credibility since 1976 Memorandum To: Expert Panel for Cosmetic Ingredient Safety Members and Liaisons From: Christina L. Burnett, Senior Scientific Writer/Analyst , CIR Date: May 15, 2020 Subject: Draft Final Safety Assessment on Punica granatum (Pomegranate)-Derived Ingredients Enclosed is the Draft Final Report of the Safety Assessment of Punica granatum (Pomegranate)-Derived Ingredients as Used in Cosmetics. (It is identified as pomegr062020rep in the pdf document.) At the December meeting, the Panel issued a Revised Tentative Report with the conclusion that the following 8 ingredients are safe in the present practices of use and concentration described
    [Show full text]
  • Biometrics and Biosecurity
    Journal of Biomedicine and Biotechnology Biometrics and Biosecurity Guest Editors: Tai-hoon Kim, Sabah Mohammed, Carlos Ramos, Osvaldo Gervasi, Wai-Chi Fang, and Adrian Stoica Biometrics and Biosecurity Journal of Biomedicine and Biotechnology Biometrics and Biosecurity Guest Editors: Tai-hoonKim, Sabah Mohammed, Carlos Ramos, Osvaldo Gervasi, Wai-Chi Fang, and Adrian Stoica Copyright © 2012 Hindawi Publishing Corporation. All rights reserved. This is a speacial issue published in “Journal of Biomedicine and Biotechnology.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board The editorial board of the journal is organized into sections that correspond to the subject areas covered by the journal. Agricultural Biotechnology Ahmad Zuhairi Abdullah, Malaysia Hari B. Krishnan, USA B. C. Saha, USA Guihua H. Bai, USA Carol A. Mallory-Smith, USA Abdurrahman Saydut, Turkey Christopher P. Chanway, Canada Xiaoling Miao, China Mariam B. Sticklen, USA Ravindra N. Chibbar, Canada Dennis P. Murr, Canada Kok Tat Tan, Malaysia Adriana S. Franca, Brazil Rodomiro Ortiz, Sweden Chiu-Chung Young, Taiwan Ian Godwin, Australia Encarnacion´ Ruiz, Spain Animal Biotechnology E. S. Chang, USA Tosso Leeb, Switzerland Lawrence B. Schook, USA Bhanu P. Chowdhary, USA James D. Murray, USA Mari A. Smits, The Netherlands Noelle E. Cockett, USA Anita M. Oberbauer, USA Leon Spicer, USA Peter Dovc, Slovenia Jorge A. Piedrahita, USA J. Verstegen, USA Scott C. Fahrenkrug, USA Daniel Pomp, USA Matthew B. Wheeler, USA Dorian J. Garrick, USA Kent M. Reed, USA Kenneth L. White, USA Thomas A.
    [Show full text]
  • Terpenoids As Potential Geroprotectors
    antioxidants Review Terpenoids as Potential Geroprotectors Ekaterina Proshkina 1 , Sergey Plyusnin 1,2 , Tatyana Babak 1, Ekaterina Lashmanova 1, Faniya Maganova 3, Liubov Koval 1,2, Elena Platonova 1,2, Mikhail Shaposhnikov 1 and Alexey Moskalev 1,2,* 1 Laboratory of Geroprotective and Radioprotective Technologies, Institute of Biology, Komi Science Centre, Ural Branch, Russian Academy of Sciences, 28 Kommunisticheskaya st., 167982 Syktyvkar, Russia; [email protected] (E.P.); [email protected] (S.P.); [email protected] (T.B.); [email protected] (E.L.); [email protected] (L.K.); [email protected] (E.P.); [email protected] (M.S.) 2 Pitirim Sorokin Syktyvkar State University, 55 Oktyabrsky Prosp., 167001 Syktyvkar, Russia 3 Initium-Pharm, LTD, 142000 Moscow, Russia; [email protected] * Correspondence: [email protected]; Tel.: +7-8212-312-894 Received: 22 May 2020; Accepted: 14 June 2020; Published: 17 June 2020 Abstract: Terpenes and terpenoids are the largest groups of plant secondary metabolites. However, unlike polyphenols, they are rarely associated with geroprotective properties. Here we evaluated the conformity of the biological effects of terpenoids with the criteria of geroprotectors, including primary criteria (lifespan-extending effects in model organisms, improvement of aging biomarkers, low toxicity, minimal adverse effects, improvement of the quality of life) and secondary criteria (evolutionarily conserved mechanisms of action, reproducibility of the effects on different models, prevention of age-associated diseases, increasing of stress-resistance). The number of substances that demonstrate the greatest compliance with both primary and secondary criteria of geroprotectors were found among different classes of terpenoids. Thus, terpenoids are an underestimated source of potential geroprotectors that can effectively influence the mechanisms of aging and age-related diseases.
    [Show full text]
  • Influence of Skin Diseases on Fingerprint Quality and Recognition
    Chapter 12 Influence of Skin Diseases on Fingerprint Quality and Recognition Michal Dolezel, Martin Drahansky, Jaroslav Urbanek, Eva Brezinova and Tai-hoon Kim Additional information is available at the end of the chapter http://dx.doi.org/10.5772/51992 1. Introduction Fingerprint recognition belongs to one of the most often used biometric technologies world‐ wide. It is believed that fingerprints could be used for the recognition of a person in nearly any case; however there exist many cases, where the fingerprint recognition could not be used. There exist some influencing factors [1] that have an impact to the process of finger‐ print recognition, e.g. the environmental influences, dirtiness on finger or the sensor, elec‐ tromagnetic radiation or diseases. This chapter deals with the circumstances which influence the quality of fingerprints – we are limited on skin diseases here, further we ex‐ plain how we can evaluate the quality of the acquired fingerprint. The fingerprint recognition consists of five main steps (see Fig. 1) [2, 3, 4]: • Fingerprint acquirement – the fingerprint is scanned using a sensor (for sensor technologies see [1]), i.e. the physical human biometric attribute is digitized and transferred to the computer. • Image enhancement – this step is very important for further processing, because the quality of the fingerprint image could be enhanced here. There are several methods used for im‐ age quality enhancement – edge filters, filtering in frequency spectrum (after Fast Fourier Transform), Gabor filter, etc. • Thresholding – the image is normally acquired with 256 gray levels, but we need a binary representation. Using various thresholding schemes (e.g.
    [Show full text]
  • Research Article Influence of Skin Diseases on Fingerprint Recognition
    Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology Volume 2012, Article ID 626148, 14 pages doi:10.1155/2012/626148 Research Article Influence of Skin Diseases on Fingerprint Recognition Martin Drahansky,1 Michal Dolezel,1 Jaroslav Urbanek,2 Eva Brezinova,3 and Tai-hoon Kim4 1 Faculty of Information Technology, Brno University of Technology, Bozetechova 2, 61266 Brno, Czech Republic 2 Faculty of Medicine and Dentistry, Palacky´ University and Faculty Hospital, I. P. Pavlova 6, 77520 Olomouc, Czech Republic 3 Faculty of Medicine, Masaryk University, Komensk´eho nam´ ˇest´ı 2, 66243 Brno, Czech Republic 4 Department of Multimedia Engineering, Hannam University, 133 Ojeong-dong, Daedeok-gu, Daejeon 306791, Republic of Korea Correspondence should be addressed to Martin Drahansky, drahan@fit.vutbr.cz Received 25 February 2012; Accepted 26 February 2012 Academic Editor: Sabah Mohammed Copyright © 2012 Martin Drahansky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. There are many people who suffer from some of the skin diseases. These diseases have a strong influence on the process of fingerprint recognition. People with fingerprint diseases are unable to use fingerprint scanners, which is discriminating for them, since they are not allowed to use their fingerprints for the authentication purposes. First in this paper the various diseases, which might influence functionality of the fingerprint-based systems, are introduced, mainly from the medical point of view. This overview is followed by some examples of diseased finger fingerprints, acquired both from dactyloscopic card and electronic sensors.
    [Show full text]
  • Prevalence and Determinants of Vitamin a Status of Women During
    Distribution Agreement In presenting this thesis or dissertation as a partial fulfillment of the requirements for an advanced degree from Emory University, I hereby grant to Emory University and its agents the non-exclusive license to archive, make accessible, and display my thesis or dissertation in whole or in part in all forms of media, now or hereafter known, including display on the world wide web. I understand that I may select some access restrictions as part of the online submission of this thesis or dissertation. I retain all ownership rights to the copyright of the thesis or dissertation. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation. _____________________________ ______________ Victor Akelo Date: Approval Sheet MODIFIABLE DETERMINANTS OF VITAMIN A DEFICIENCY AMONG PREGNANT WOMEN PARTICIPATING IN THE MAMA SASHA COHORT STUDY OF VITAMIN A IN WESTERN KENYA By Victor Akelo, MPH Hubert Department of Global Health _________________________________________ [Chair’s signature] Amy Webb Girard, PhD Committee Chair _________________________________________ [Member’s signature] Paul S. Weiss, MS Committee Member _________________________________________ [Member’s signature] Deborah A. McFarland, PhD, MPH Committee Member 2 | Page Draft version 1.0 MODIFIABLE DETERMINANTS OF VITAMIN A DEFICIENCY AMONG PREGNANT WOMEN PARTICIPATING IN THE MAMA SASHA COHORT STUDY OF VITAMIN A IN WESTERN KENYA By Victor Akelo Master of Public Health Global Health (Infectious Diseases) Thesis
    [Show full text]
  • Carotenoids and Retinoids in Human Nutrition
    Crilical Reviews in Food Science and NUlrilion, 31 (liZ): 103-163 (1992) Carotenoids and Retinoids in Human Nutrition E-Siong Tee Division of Human Nutrition, Institute for Medical Research, 50588 Kuala Lumpur, Malaysia Referee: C. Y. Lee, Ph.D., Department of Food Science and Technology, Cornell University, Geneva, New York 14456 ABSTRACT: Since the discovery of vitamin A as a fat-soluble growth factor in thl~ early part of the century. research into carotenoids and retinoids has attracted the attention of many scientists. These two groups of compounds are still being actively studied all over the world since many gaps in knowledge exist and new frontiers are being pursued. Recent developments in studies into the possible roles of carotl~noids and retinoids beyond their classical functions in vision have created a great deal of excitement in the biomedical community. This review covers a wide range of topics pertaining to these two closely related compounds. Particular emphasis is given to the functions of these compounds and their roles in human nutrition. V2,rious aspects of vitamin A deficiency and ,tudies on carotenoids and retmoids in cancer development and prevention are reviewed in some detail. KEY WORDS: carotenoids. retinoids, human nutrition, vitamin A deficiency, cancer development and prevention. I. INTRODUCTION chemical synthesis are all more recent achieve­ ments, accomplished during the 20th century. Some 75 years ago, vitamin A was discov-­ ered as a fat-soluble growth factor present in liver Vitamin A, or retinol, is an essential nutrient and recognized as an essential biochemical for for man and all mammalian species since it can­ normal vision in man and animals.
    [Show full text]
  • E-Poster Presentations
    Turk J Int Med 2021 E-Poster Presentations Adult Still’s Disease Activation or A Case of Autoimmune Polyglan- EP001 EP002 COVID-19 Infection: A Case Report dular Syndrome Presenting with Latent Autoimmune Diabetes Şeyma ESENBUĞA1, Belkıs Nihan COŞKUN2, Altuğ GÜNER2, Zeynep YILMAZ BOZKURT2, Nihal LERMİ2, Yavuz PEHLİVAN2, Ediz DALKILIÇ2 Coşkun ATEŞ1, Yasemin ÜNSAL1, Ensar AYDEMİR1, Özen ÖZ GÜL1, Soner CANDER1, Canan ERSOY1, Erdinç ERTÜRK1 1Bursa Uludağ University Faculty of Medicine, Department of Internal Medicine, Bursa, Turkey 1Bursa Uludağ University Faculty of Medicine, Division of Endocrinology and 2Bursa Uludağ University Faculty of Medicine, Department of Internal Medicine, Metabolic Diseases, Bursa, Turkey Division of Rheumatology, Bursa, Turkey Background Adult Still’s Disease (ASD) is a systemic inflam- Background Autoimmune polyglandular syndrome (OPS) is matory disease manifested by fever, arthritis, and salmon-co- a group of autoimmune diseases characterized by the failure lored maculopapular rash. It may accompany pharyngitis, of at least two endocrine glands in hormone production. OPS splenomegaly, generalized lymphadenopathy, and serositis. In type 1 is seen in childhood and is diagnosed with hypoparath- the COVID-19 pandemic, COVID-19 findings can be confused yroidism, Addison’s disease, and candida infection involving with the exacerbation of ASD. We aimed to present a patient the skin or mucous membranes. OPS type 2 (Type 1 diabetes with a diagnosis of ASD who applied to our outpatient clinic with Addison’s disease or autoimmune thyroid disease), OPS type 3 (Autoimmune thyroid disease with other autoimmu- with fever and rash. ne diseases other than Addison) and OPS Type 4 (Addison’s Material and Methods A 50-year-old female patient diagnosed disease with one or more organ-specific Type 1 and type 2 with ASD in 2017 with complaints of common joint pain, fe- autoimmune diseases that do not include major components ver, rash, and sore throat was being followed up with predni- seen in OPS).
    [Show full text]
  • Appendix a Acid-Base Calculations
    Appendix A Acid-Base Calculations A. 1. IO NIC STRENGTH Ionic strength (/) is a measure of ion concentration, de­ and based on Eq. (1.2) fined by the equation (W] = (1.0 X 10-14)/0.040 = 2.5 X 10- 13 so that where c. is the concentration of ion i, z. is the charge of ' ion i, and L is "the sum ~f." pH = -log[W] = -log(2.5 X 10- 13) = 12.6 = 13 Problem: What is the ionic strength of a O.lM solu­ tion of (NH4 ) 2SO4 ? Solution: Each "molecule" of (NH4) 2SO4 yields two A.3. HE DERSON- H ASSE LBALCH NH; ions and one So~- ion. Hence, EQUATIO N [NHl l = c 1 = 0.2M; z1 = + 1 [So~ - ]= c2 = 0.1M; z2 = - 2 Problem 1: Calculate the pH of a solution made by mix­ 1 I = I/2 ~{ (0.2 X 12) + (0.1 X ( - 2)2]} = 0.3 ing 15.0mlof 1.00 X 10- MK2HP04 and25.0mlof2.00 2 X 10- MKH2P04 . Solution: Molar concentrations of the two salts in the A.2. pH final volume (15.0 + 25.0 = 40.0 ml) are: 1 forK2HP04 : 15.0 X (1.00 X 10- )/40.0 = 0.0375M Problem 1: What is the pH of 0.01 OM HCI, assuming that for KH2P04 : 25.0 X (2.00 X 10- 2)/40.0 = 0.01 25M the HCl is 100% ionized? Substituting these values into the Henderson- Hasselbalch Solution: equation and using pK~ = 7.21 yields [W] = O.OlOM = 1.0 X 10-2M pH = -log[W] = -log(l.O X 10- 2) = 2.0 (0.0375) pH = 7.21 +log (0.0125) = 7.69 Problem 2: What is the pH of 0.020M Ca(OH)2 , as­ suming that it is 100 % ionized? Problem 2: Given that lactic acid (HA = CH3 - Solution: Since each "molecule" of Ca(OH)2 yields CHOH -COOH; A- = CH3 -CHOH - coo- ) has a two OH- ions, pK~ of 3.86, calculate the percent of lactic acid present in 503 504 APPENDIX A its dissociated form (A-) at a pH that is one unit above its (0.400- x) = 0.065 mol ofK2HP04/liter pK~ (i.e., at pH 4.86).
    [Show full text]